Combination Antifungals for Candida auris : using the hollow fibre model to study an azole/5FC combination for a WHO priority pathogen

MRC · United Kingdom government procurement

This opportunity is now closed. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Resistance to antibiotics is a major global health problem. The main focus has been on antibiotic resistance in bacteria, but drug resistance in fungal infections is a growing part of this problem.
This is typified by the emergence of a new species of pathogenic fungus. Called Candida auris, a type of harmful yeast discovered as recently as 2009 and has since spread around the world. It is extremely resistant to most of the antifungal drugs currently available. It also spreads quickly within hospital environments, and outbreaks can be very difficult to control- it has resulted in whole intensive care units (ICUs) having to be completely shut down, including in the UK.
If it gets into the bloodstream, it has a very high mortality of up to 70%. There is therefore an urgent need to find better treatments for this infection. The World Health Organization (WHO) have designated this a pathogen of "critical" public health importance.
This project will investigate a combination of antifungal drugs as a potential treatment for Candida auris. We will test flucytosine (also known as 5FC) in combination with an antifungal in the azole class (isavuconazole or posaconazole). Using a single antifungal drug, resistance is likely to emerge, but combination therapy may prevent this. Combination antifungal therapy has proved effective in other serious fungal infections.
Clinical trials in patients are ultimately needed to test the best treatments but pre clinical laboratory data is needed to choose the best candidate treatments to go forward for clinical trial. To generate this information we will use a laboratory model known as the Hollow Fibre Infection Model. This is an experimental laboratory system mimics the way drugs circulate in the human body and then act against microbes. It has been successfully used to test a variety of antibiotics for different pathogens. This model has significant advantage over animal experiments. It is cheaper to run and has fewer ethical challenges,...

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyMRC
CountryUnited Kingdom
CategoryResearch & Development
PublishedOctober 06, 2024
Procurement stageActive solicitation
ClosedClosing date not published
StatusClosed — no longer accepting responses
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: UK Research and Innovation (UKRI) — Open Government Licence v3.0.

Browse Similar Open Opportunities in United Kingdom

University Interactions - NDA Research Portfolio
University Interactions - NDA Research Portfolio - Single Supplier Framework
Disposal System Science & Technology Framework
MOPAC: Research Services: Public Attitude Survey, User Satisfaction Survey & Telephone & Digital Investigation Unit
UKHSA Knowledge, Attitudes and Behavioural Research Preliminary Market Engagement Notice
Highland Deephaven: Strategic Masterplanning & Feasibility Study
Digital Transformation and Research & Innovation Consultancy Open Framework
Gambling Research Services

See every United Kingdom Research & Development opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free United Kingdom Research & Development intelligence report in your inbox

A personalized report on United Kingdom Research & Development opportunities, emailed in 5-10 minutes. One per month, no account needed.